InnoCare Pharma Limited (OTCMKTS:INCPF – Get Free Report) was the target of a significant drop in short interest during the month of June. As of June 15th, there was short interest totaling 445,268 shares, a drop of 63.0% from the May 31st total of 1,202,243 shares. Based on an average trading volume of 0 shares, the short-interest ratio is presently ∞ days.
InnoCare Pharma Stock Performance
Shares of INCPF stock opened at $1.55 on Friday. InnoCare Pharma has a 52-week low of $1.55 and a 52-week high of $2.31. The stock’s 50-day moving average price is $1.55 and its 200 day moving average price is $1.75.
Analyst Ratings Changes
Separately, Morgan Stanley upgraded shares of InnoCare Pharma to an “overweight” rating in a research report on Thursday, May 28th. One research analyst has rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy”.
About InnoCare Pharma
InnoCare Pharma Ltd is a China-based, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule targeted therapies for oncology. Headquartered in Shenzhen, Guangdong Province, the company leverages structure-based drug design and comprehensive preclinical screening to advance drug candidates that address high-unmet-need cancers.
The company’s development pipeline comprises multiple small-molecule inhibitors in various stages of preclinical and early clinical evaluation.
Recommended Stories
- Five stocks we like better than InnoCare Pharma
- Why Alphabet’s Pullback May Be an Opportunity in Disguise
- Capri’s Turnaround Is Taking Shape, But Is the Stock a Buy Yet?
- SpaceX Has Real Value—But These 3 Stocks Have Better Odds Right Now
- 3 Stocks That Could Benefit as the Robotaxi Race Heats Up
Receive News & Ratings for InnoCare Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InnoCare Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
